TME Pharma


TME Pharma
is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned. 

SNO 2023 poster:
Lastest data in Glioblastoma from the expansion arm with
NOX-A12 + radiotherapy + anti-VEGF

Press Release


2024, April 25
06:00 p.m.

TME Pharma publishes 2023 financial results and provides operating update

2024, April 23
08:00 a.m.

TME Pharma announces 33% of patients receiving NOX-A12 in combination with bevacizumab and radiotherapy achieve two-year survival in GLORIA Phase 1/2 trial in brain cancer

2024, April 02
08:00 p.m.

TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer

Events

LSX World Congress

Aram Mangasarian, Ewelina Staniuk
April 29 – 30 | London, UK

Bio International Convention

Dirk Eulberg, Ewelina Staniuk
June 3 – 6 | San Diego, CA

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.